View Post

How 3,500 women helped save my sister’s life

In Clinical Trials by Barbara Jacoby

By: Lindsey Wahlstrom-Edwards Source: antidote.me I have never been one for anniversaries, but life after my sister’s diagnosis with triple positive breast cancer seems to be full of them. December 1st she found a tumor. December 15th we learned it was cancer. December 17th – her 35th birthday – we learned it was HER2+. December 26th – the fourth anniversary …

View Post

Top 5 Myths About Cancer Clinical Trials

In Clinical Trials by Barbara Jacoby

By: Jill Weberding From: medium.com Clinical trials are the only avenue that advances in medicine occur. Every approved drug or treatment must go through the clinical trial process. With the increasing pace of science and technology advances, there were 19 drugs with new approvals for cancer treatment in 2018 according to “CenterWatch” (n.d.). Despite the excitement of tapping into the …

View Post

New SU2C teams accelerate clinical trials for difficult breast & prostate cancers

In Clinical Trials by Barbara Jacoby

Source: Stand Up To Cancer From: eurekalert.org Stand Up To Cancer (SU2C) is launching teams of experts to lead innovative attacks on two types of cancer that have defied conventional treatment: triple-negative breast cancer (TNBC) in women and metastatic prostate cancer in men. The $6 million effort supported by SU2C Catalyst Founding Collaborator, Genentech, a member of the Roche Group, …

View Post

Startup joins Roche to hold clinical trials for double-whammy cancer drug

In Clinical Trials by Barbara Jacoby

By: Shoshanna Solomon From: imesofisrael.com DSP-107, developed by KAHR Medical, hopes to have dual impact: tag cancer cells, and boost activity of the immune cells that target them KAHR Medical, an Israeli biopharmaceutical company, says it is developing a second generation class of  immunotherapy drugs that it hopes will be more effective in tackling cancer, based on the lessons learned …

View Post

CRISPR may explain why so many experimental cancer drugs fail

In Clinical Trials by Barbara Jacoby

By: Sally Robertson, B.Sc. From: news-medical.net Researchers in the United States have discovered that many experimental cancer drugs may be missing their molecular targets and are instead succeeding in unintended ways, some of which could have toxic effects. Using the gene-editing tool CRISPR–Cas9 to investigate how ten cancer drugs interact with their protein target, the researchers found that the proteins …

View Post

Amgen’s drug targeting ‘undruggable’ protein shines at lung cancer conference

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose. A drug in development for a protein target once thought unreachable by pharmaceutical means has new data showing its potential efficacy in lung …

View Post

Novel Approaches Push the Envelope in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Hergert From: onclive.com Developments in antibody-drug conjugates (ADCs), TKIs, and neoadjuvant interventions are improving outcomes for patients with early- and advanced-stage HER2-positive breast cancer, said Douglas K. Marks, MD, adding that investigational approaches could expand the treatment armamentarium even further. “For the treating oncologists, the options to offer patients who previously had a very poor prognosis are becoming …

View Post

Preclinical study reveals the impact of age on immunotherapy treatment for breast cancer

In Clinical Trials by Barbara Jacoby

Source: Brigham and Women’s Hospital From: eurekalert.org Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient’s immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer (TNBC). Despite the fact that most breast cancer …

View Post

FAK protein linked to chemotherapy resistance in ovarian cancer

In Clinical Trials by Barbara Jacoby

Source: University of California – San Diego From: sciencedaily.com Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance and mortality remain high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer. A new study in the journal eLife by University of California San Diego School of …

View Post

Dynamic duo in Pinehurst appreciates opportunity to participate in clinical trial

In Clinical Trials by Barbara Jacoby

From: sandhillssentinel.com While FirstHealth of the Carolinas has earned widespread acclaim as a national leader in community health, Sandhills residents may not know of a superpower within the system that offers opportunities for patients in the region and worldwide: its extensive clinical trials program. “FirstHealth offers a wide array of clinical trials that far exceeds the average for regional medical …